Form 4: Humacyte Director Michael Constantino Receives Stock Options

Director Michael T. Constantino was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Summary

• Director Michael T. Constantino received a grant of 80,000 stock options for Humacyte, Inc. (HUMA) common stock.
• The options have an exercise price of $1.08 per share.
• The grant was issued on June 11, 2026, with an expiration date of June 11, 2036.
• The options follow a standard vesting schedule over four years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a signal of operational performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• The value of the options is dependent on the future market performance of HUMA common stock.

Future Outlook

The options vest over a four-year period, indicating a long-term commitment by the director to the company's growth.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized to achieve long-term clinical and commercial milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard equity compensation practices for board members in the life sciences industry.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of the first 25% of options on June 11, 2027.

Key Dates

Keywords

Humacyte, HUMA, Form 4, Insider Trading, Stock Options, Director Compensation